An Overview of Cellular and Molecular Determinants Regulating Chemoresistance in Pleural Mesothelioma

Our plain-English summary of An Overview of Cellular and Molecular Determinants Regulating Chemoresistance in Pleural Mesothelioma, by L. Cortes-Dericks, D. Galetta (Cancers, 2025).

The study

• Authors: L. Cortes-Dericks, D. Galetta
• Journal: Cancers
• Published: 2025;17(6)
• Type of article: Review
• Cited by: 3 articles, as counted by NIH iCite
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant pleural mesothelioma (PM) is a highly aggressive disease of the lung pleura associated with poor prognosis. Despite advances in improving the clinical management of this malignancy, there is no effective chemotherapy for refractory or relapsing PM. The acquisition of resistance to standard and targeted therapy in this disease is a foremost concern; therefore, a deeper understanding of the complex factors surrounding the emergence of drug resistance is deemed necessary. In this review, we will present broad insights into various cellular and molecular concepts, accounting for the recalcitrance of PM to chemotherapy, including signaling networks regulating drug tolerance, drug resistance-associated proteins, genes, and miRNAs, as well as the critical role of cancer stem cells. Identification of the biological determinants and their associated mechanisms may provide a framework for the development of appropriate treatment.

In plain English

This article is a narrative review, not a new study. The authors, from the University of Hamburg and a hospital in Turin, summarized published research on why pleural mesothelioma often resists chemotherapy. They described the disease as strongly associated with asbestos exposure, and the drugs discussed were mainly the standard treatments cisplatin and pemetrexed. The article does not describe how the reviewed studies were found or selected. Most of the research reviewed was laboratory work on mesothelioma cell lines, tumor spheroids and tissue samples, with some mouse models and patient groups. The authors grouped the findings into four categories: cell signaling networks; proteins and genes such as BAP1, metallothioneins and thymidylate synthase; small regulatory molecules called microRNAs; and cancer stem cells. They noted that one reviewed study found no link between the drug-pump proteins P-glycoprotein, MRP1 and MRP2 in tumor tissue and patient survival. The authors concluded that the mechanisms of drug resistance in pleural mesothelioma are still largely undetermined. They suggested that identifying these factors may help in developing new drugs and patient-tailored treatment combinations.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Narrative review of published research; no method for finding or selecting studies is described
• Who was studied: No new population was studied. The review covered published studies, mostly laboratory studies of pleural mesothelioma (PM) cell lines, spheroids and tissue specimens, plus some mouse models and patient cohorts. The number of studies and the date range are not stated; the article lists 117 references.
• Exposure: Chemotherapy and targeted drugs, mainly platinum drugs (cisplatin) and pemetrexed. Asbestos is mentioned only as the background cause of PM, with no fiber types specified.
• Main results:
  • The review grouped the reported determinants of drug resistance in PM into four categories: signaling networks, proteins and genes, microRNAs, and cancer stem cells.
  • A reviewed study (Oehl et al.) of PM patients and cell lines reported that, in laboratory experiments, alterations in the BAP1 gene led to resistance to cisplatin.
  • A reviewed study (Soini et al.) found that levels of P-glycoprotein, MRP1 and MRP2 in PM tissues showed no correlation with patient survival.
  • A reviewed study (Giovannetti et al.) reported that patients with low levels of the folate transporter PCFT had significantly lower overall survival in both test and validation cohorts. No numbers are given in the review.
  • Earlier work by the first author's group, described in the review, found a putative cancer stem cell population in PM cell lines whose ALDH activity cisplatin treatment failed to reduce.
• The authors' conclusion: The authors concluded that the mechanisms of drug resistance in PM are still largely undetermined. They suggested that identifying resistance-associated proteins, genes, microRNAs, signaling molecules and cancer stem cells may support the development of new drugs and patient-tailored combination treatments.

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Pleura, Prognosis, Chemotherapy, Targeted Therapy, STEM.

Related studies

• Determinants of Response to Immune Checkpoint Blockade in Pleural Mesothelioma: Molecular, Immunological, and Clinical Perspectives — M. Delsignore, G. Cassinari, et al. (2025)
• Cellular and molecular mechanisms of asbestos-induced fibrosis — R. Robledo, B. Mossman (1999)
• Possible cellular and molecular mechanisms for asbestos carcinogenicity — C. Walker, J. Everitt, et al. (1992)
• Asbestos-induced cellular and molecular alteration of immunocompetent cells and their relationship with chronic inflammation and carcinogenesis — H. Matsuzaki, M. Maeda, et al. (2012)
• Cellular and molecular parameters of mesothelioma — M.E. Ramos-Nino, J.R. Testa, et al. (2006)
• Cellular and molecular mechanisms of asbestos carcinogenicity: implications for biopersistence — J.C. Barrett (1994)

Browse more research in Cancers, or return to medical research.